Skip to nav Skip to content
John  Cleveland

John Cleveland, PhD

Executive Vice President, Center Director

Program: Tumor Microenvironment and Metastasis

Research Program: Cancer Biology & Evolution Program


  • Overview

    Dr. Cleveland’s research has been broadly focused on the molecular pathogenesis of cancer, where he has been a leader in interrogating the regulation and role of oncogenes and tumor suppressors in controlling cancer cell growth and survival, and in defining new targets that play essential roles in the development and maintenance of cancer. 


    • Tumor Microenvironment and Metastasis
    • Malignant Hematology
    • Cancer Biology & Evolution Program
    • Melanoma & Skin Cancer Center of Excellence
    • Center of Excellence for Evolutionary Therapy
    • Lung Cancer Center of Excellence

    Education & Training


    • Wayne State University School of Medicine, PhD - Immunology and Microbiology


    • Roswell Park Cancer Institute - Health Psychology
  • Research Interest

    Dr. John Cleveland was trained at the National Cancer Institute under the direction of Dr. Ulf R. Rapp (who discovered Raf family oncogenes) and began his career as an Assistant Professor in the Department of Biochemistry of St. Jude Children’s Research Hospital in 1989. He became a Full Professor in 2000 and was also Program Leader of the Signal Transduction Program. In November of 2006 he was recruited to become founding Chair of the Department of Cancer Biology at The Scripps Research Institute. He joined the Moffitt Cancer Center on July 1 as Associate Center Director of Basic Science, where he holds the Cortner Couch Endowed Chair and the academic appointment of Senior Member and Professor in the Department of Tumor Biology. Dr. Cleveland’s research has been broadly focused on the molecular pathogenesis of cancer, where he has been a leader in interrogating the regulation and role of oncogenes and tumor suppressors in controlling cancer cell growth and survival, and in defining new targets that play essential roles in the development and maintenance of cancer. In line with the mission of Moffitt, all his lab’s is dedicated towards developing new agents and strategies for the prevention and treatment of cancer. Dr. Cleveland has been continuously funded through NIH R01 grants since 1991. Dr. Cleveland has been and continues to be an invited lecturer at many Institutes and at several national and international scientific meetings. Over the years, Dr. Cleveland has supervised more than 35 postdoctoral researchers and graduate students, and over 24 of these have gone on to establish independent and successful careers in academia, or in the biotechnology and pharmaceutical industry sectors. Dr. Cleveland has published over 150 peer-reviewed articles and 40 book chapters and review articles in the cancer research field. Several of these have been published in top-tier scientific journals, including Cell, Molecular Cell, Cancer Cell, Nature, Nature Medicine, Genes & Development, Proceedings of the National Academy of Sciences, The EMBO Journal, Molecular and Cellular Biology, Cancer Research and the Journal of Experimental Medicine. Dr. Cleveland has been a long standing Member of the American Association of Sciences, the American Society of Microbiology and of the American Association of Cancer Research. Dr. Cleveland has also served as an Editor for several prestigious journals, including Molecular Biology of the Cell and Molecular and Cellular Biology, and as an Associate Editor for Cell Death and Differentiation and for Cancer Research. He also has a long history as a Reviewer for Study Sections, for both the American Cancer Society (six years) and for the National Institutes of Health (NIH, for ~20 years); including as Chair of the Parent Committee (NCI-C) that reviews Program Project Grants for the National Cancer Institute. Finally, he has also served as a Member of the Extramural Scientific Advisory Boards for The University of Arizona (for their SPORE and PPG programs), The Roswell Park Cancer Institute, The Blood Research Institute, and for the Florida Center for Brain Tumor Research at the University of Florida. At Moffitt he co-chairs the Core Leadership Committee, and serves on the Research Executive Committee, the Research Institute Steering Committee and the Scientific Leadership Committee.

  • Publications

    • Yun S, Cleveland JL. Transcriptional Plasticity Drives IMiD and p300 Inhibitor Resistance in Multiple Myeloma. Blood Cancer Discov. 2024 Jan.5(1):5-7. Pubmedid: 38085608. Pmcid: PMC10772544.
    • Sasamoto N, Stewart PA, Wang T, Thompson ZJ, Yoder SJ, Hecht JL, Cleveland JL, Conejo-Garcia J, Fridley BL, Terry KL, Tworoger SS. Associations between prediagnostic aspirin use and ovarian tumor gene expression. Cancer Med. 2023 Sep.12(17):18405-18417. Pubmedid: 37525619. Pmcid: PMC10523980.
    • Elmarsafawi AG, Hesterberg RS, Fernandez MR, Yang C, Darville LN, Liu M, Koomen JM, Phanstiel Iv O, Atkins R, Mullinax JE, Pilon-Thomas SA, Locke FL, Epling-Burnette PK, Cleveland JL. Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells. JCI Insight. 2023 Sep.8(18). Pubmedid: 37581943. Pmcid: PMC10561731.
    • Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Res. 2023 Nov.83(21):3504-3506. Pubmedid: 37732910.
    • Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Mol Cancer Res. 2023 Nov.21(11):1139-1141. Pubmedid: 37732893.
    • Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Epidemiol Biomarkers Prev. 2023 Nov.32(11):1482-1484. Pubmedid: 37732892.
    • Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Mol Cancer Ther. 2023 Nov.22(11):1245-1247. Pubmedid: 37732909.
    • Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Blood Cancer Discov. 2023 Nov.4(6):420-422. Pubmedid: 37732908. Pmcid: PMC10621678.
    • Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Prev Res (Phila). 2023 Nov.16(11):591-594. Pubmedid: 37732897.
    • Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Clin Cancer Res. 2023 Nov.29(21):4338-4340. Pubmedid: 37732904.
    • Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Immunol Res. 2023 Nov.11(11):1446-1448. Pubmedid: 37732896.
    • Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Discov. 2023 Nov.13(11):2316-2318. Pubmedid: 37702762.
    • Tong Y, Lee Y, Liu X, Childs-Disney JL, Suresh BM, Benhamou RI, Yang C, Li W, Costales MG, Haniff HS, Sievers S, Abegg D, Wegner T, Paulisch TO, Lekah E, Grefe M, Crynen G, Van Meter M, Wang T, Gibaut QMR, Cleveland JL, Adibekian A, Glorius F, Waldmann H, Disney MD. Programming inactive RNA-binding small molecules into bioactive degraders. Nature. 2023 Jun.618(7963):169-179. Pubmedid: 37225982. Pmcid: PMC10232370.
    • Nakanishi S, Li J, Berglund AE, Kim Y, Zhang Y, Zhang L, Yang C, Song J, Mirmira RG, Cleveland JL. The Polyamine-Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma. Blood Cancer Discov. 2023 Jul.4(4):294-317. Pubmedid: 37070973. Pmcid: PMC10320645.
    • Burger KL, Fernandez MR, Meads MB, Sudalagunta PR, Oliveira PS, Renatino Canevarolo R, Alugubelli RR, Tungsevik A, De Avila G, Silva M, Graeter AI, Dai H, Vincelette ND, Prabhu A, Magaletti D, Yang C, Li W, Kulkarni A, Hampton OA, Koomen JM, Roush WR, Monastyrskyi A, Berglund AE, Silva AS, Cleveland JL, Shain KH. CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma. Cancer Res. 2023 Dec.83(23):3901-3919. Pubmedid: 37702657. Pmcid: PMC10690099.
    • Hesterberg RS, Liu M, Elmarsafawi AG, Koomen JM, Welsh EA, Hesterberg SG, Ranatunga S, Yang C, Li W, Lawrence HR, Rodriguez PC, Berglund AE, Cleveland JL. TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate. Cancer Immunol Res. 2022 Oct.10(10):1263-1279. Pubmedid: 35969234. Pmcid: PMC9662872.
    • Peng V, Cao S, Trsan T, Bando JK, Avila-Pacheco J, Cleveland JL, Clish C, Xavier RJ, Colonna M. Ornithine decarboxylase supports ILC3 responses in infectious and autoimmune colitis through positive regulation of IL-22 transcription. Proc Natl Acad Sci U S A. 2022 Nov.119(45):e2214900119. Pubmedid: 36279426. Pmcid: PMC9659397.
    • Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, List AF, Wei S, Eksioglu EA. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther. 2022 Jun.30(6):2315-2326. Pubmedid: 35150889. Pmcid: PMC9171150.
    • Daniel Grass G, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-Roca JF. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Jul.113(3):635-647. Pubmedid: 35289298. Pmcid: PMC9250625.
    • Freischel AR, Teer JK, Luddy K, Cunningham J, Artzy-Randrup Y, Epstein T, Tsai KY, Berglund A, Cleveland JL, Gillies RJ, Brown JS, Gatenby RA. Evolutionary Analysis of TCGA Data Using Over- and Under- Mutated Genes Identify Key Molecular Pathways and Cellular Functions in Lung Cancer Subtypes. Cancers (Basel). 2022 Dec.15(1). Pubmedid: 36612014. Pmcid: PMC9817988.
    • Fernandez MR, Schaub FX, Yang C, Li W, Yun S, Schaub SK, Dorsey FC, Liu M, Steeves MA, Ballabio A, Tzankov A, Chen Z, Koomen JM, Berglund AE, Cleveland JL. Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. Cancer Res. 2022 Apr.82(7):1234-1250. Pubmedid: 35149590. Pmcid: PMC9004540.
    • Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 Apr.81(4):325-330. Pubmedid: 33303244.
    • Alfonso JCL, Grass GD, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Torres-Roca JF, Enderling H. Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. Neoplasia. 2021 Nov.23(11):1110-1122. Pubmedid: 34619428. Pmcid: PMC8502777.
    • Nakanishi S, Cleveland JL. Polyamine Homeostasis in Development and Disease. Med Sci (Basel). 2021 May.9(2). Pubmedid: 34068137. Pmcid: PMC8162569.
    • Yun S, Vincelette ND, Yu X, Watson GW, Fernandez MR, Yang C, Hitosugi T, Cheng CH, Freischel AR, Zhang L, Li W, Hou H, Schaub FX, Vedder AR, Cen L, McGraw KL, Moon J, Murphy DJ, Ballabio A, Kaufmann SH, Berglund AE, Cleveland JL. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discov. 2021 Mar.2(2):162-185. Pubmedid: 33860275. Pmcid: PMC8043621.
    • Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, Meads MB, Ren Y, Li T, Sun J, Fahmi NA, Singh S, Sehgal L, Wang X, Silva AS, Sotomayor EM, Shain KH, Cleveland JL, Wang M, Zhang W, Qi J, Shah BD, Tao J. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep. 2021 Mar.34(11):108870. Pubmedid: 33730585. Pmcid: PMC8057695.
    • Awasthi S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, Kensler KH, Serna AN, Vidal AC, You S, Freeman MR, Davicioni E, Liu Y, Karnes JR, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk SP, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2021 Jan.27(1):320-329. Pubmedid: 33037017. Pmcid: PMC8042600.
    • Lin HY, Huang PY, Cheng CH, Tung HY, Fang Z, Berglund AE, Chen A, French-Kwawu J, Harris D, Pow-Sang J, Yamoah K, Cleveland JL, Awasthi S, Rounbehler RJ, Gerke T, Dhillon J, Eeles R, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Neal DE, Nielsen SF, Nordestgaard BG, Gronberg H, Wiklund F, Giles GG, Haiman CA, Travis RC, Stanford JL, Kibel AS, Cybulski C, Khaw KT, Maier C, Thibodeau SN, Teixeira MR, Cannon-Albright L, Brenner H, Kaneva R, Pandha H, Srinivasan S, Clements J, Batra J, Park JY. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci Rep. 2021 Apr.11(1):9264. Pubmedid: 33927218. Pmcid: PMC8084951.
    • Zahedi K, Brooks M, Barone S, Rahmati N, Murray Stewart T, Dunworth M, Destefano-Shields C, Dasgupta N, Davidson S, Lindquist DM, Fuller CE, Smith RD, Cleveland JL, Casero RA, Soleimani M. Ablation of polyamine catabolic enzymes provokes Purkinje cell damage, neuroinflammation, and severe ataxia. J Neuroinflamm. 2020 Oct.17(1):301. Pubmedid: 33054763. Pmcid: PMC7559641.
    • Sierra JC, Piazuelo MB, Luis PB, Barry DP, Allaman MM, Asim M, Sebrell TA, Finley JL, Rose KL, Hill S, Holshouser SL, Casero RA, Cleveland JL, Woster PM, Schey KL, Bimczok D, Schneider C, Gobert AP, Wilson KT. Spermine oxidase mediates Helicobacter pylori-induced gastric inflammation, DNA damage, and carcinogenic signaling. Oncogene. 2020 May.39(22):4465-4474. Pubmedid: 32350444. Pmcid: PMC7260102.
    • Walton K, Fernandez MR, Sagatys EM, Reff J, Kim J, Lee MC, Kiluk JV, Hui JYC, McKenna D, Hupp M, Forster C, Linden MA, Lawrence NJ, Lawrence HR, Pidala J, Pavletic SZ, Blazar BR, Sebti SM, Cleveland JL, Anasetti C, Betts BC. Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity. JCI Insight. 2020 May.5(9). Pubmedid: 32255769. Pmcid: PMC7253027.
    • Yurdagul A, Subramanian M, Wang X, Crown SB, Ilkayeva OR, Darville L, Kolluru GK, Rymond CC, Gerlach BD, Zheng Z, Kuriakose G, Kevil CG, Koomen JM, Cleveland JL, Muoio DM, Tabas I. Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury. Cell Metab. 2020 Mar.31(3):518-533.e10. Pubmedid: 32004476. Pmcid: PMC7173557.
    • Maharaj K, Powers JJ, Achille A, Mediavilla-Varela M, Gamal W, Burger KL, Fonseca R, Jiang K, Miskin HP, Maryanski D, Monastyrskyi A, Duckett DR, Roush WR, Cleveland JL, Sahakian E, Pinilla-Ibarz J. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020 Jul.4(13):3072-3084. Pubmedid: 32634240. Pmcid: PMC7362385.
    • Creed JH, Berglund AE, Rounbehler RJ, Awasthi S, Cleveland JL, Park JY, Yamoah K, Gerke TA. Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk. Cancer Epidemiol Biomarkers Prev. 2020 Jan.29(1):246-253. Pubmedid: 31757784. Pmcid: PMC7942810.
    • Parag-Sharma K, O'Banion CP, Henry EC, Musicant AM, Cleveland JL, Lawrence DS, Amelio AL. Engineered BRET-Based Biologic Light Sources Enable Spatiotemporal Control over Diverse Optogenetic Systems. ACS Synth Biol. 2020 Jan.9(1):1-9. Pubmedid: 31834783. Pmcid: PMC7875091.
    • Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al-Ali N, Lancet JE, Cleveland JL, Padron E, List AF. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020 Dec.136(24):2812-2823. Pubmedid: 32730593. Pmcid: PMC7731792.
    • Hesterberg RS, Beatty MS, Han Y, Fernandez MR, Akuffo AA, Goodheart WE, Yang C, Chang S, Colin C, Alontaga AY, McDaniel J, Mailloux AW, Billington JMR, Yue L, Russell S, Gillies RJ, Yun SY, Ayaz M, Lawrence NJ, Lawrence H, Yu XZ, Fu J, Darville LN, Koomen JM, Ren X, Messina J, Jiang K, Garrett TJ, Rajadhyaksha A, Cleveland JL, Epling-Burnette PK. Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes. Blood. 2020 Aug.136(7):857-870. Pubmedid: 32403132. Pmcid: PMC7426646.
    • Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019 Sep.84:106194. Pubmedid: 31357093. Pmcid: PMC7375354.
    • Cook LM, Frieling JS, Nerlakanti N, McGuire JJ, Stewart PA, Burger KL, Cleveland JL, Lynch CC. Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis. Oncogene. 2019 Oct.38(44):6959-6969. Pubmedid: 31409900. Pmcid: PMC7771554.
    • Renner K, Bruss C, Schnell A, Koehl G, Becker HM, Fante M, Menevse AN, Kauer N, Blazquez R, Hacker L, Decking SM, Bohn T, Faerber S, Evert K, Aigle L, Amslinger S, Landa M, Krijgsman O, Rozeman EA, Brummer C, Siska PJ, Singer K, Pektor S, Miederer M, Peter K, Gottfried E, Herr W, Marchiq I, Pouyssegur J, Roush WR, Ong S, Warren S, Pukrop T, Beckhove P, Lang SA, Bopp T, Blank CU, Cleveland JL, Oefner PJ, Dettmer K, Selby M, Kreutz M. Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy. Cell Rep. 2019 Oct.29(1):135-150.e9. Pubmedid: 31577944.
    • Carper MB, Troutman S, Wagner BL, Byrd KM, Selitsky SR, Parag-Sharma K, Henry EC, Li W, Parker JS, Montgomery SA, Cleveland JL, Williams SE, Kissil JL, Hayes DN, Amelio AL. An Immunocompetent Mouse Model of HPV16(+) Head and Neck Squamous Cell Carcinoma. Cell Rep. 2019 Nov.29(6):1660-1674.e7. Pubmedid: 31693903. Pmcid: PMC6870917.
    • Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer P D. 2019 May.22(2):292-302. Pubmedid: 30367117. Pmcid: PMC6760558.
    • Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J, Tao J. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell. 2019 May.35(5):752-766.e9. Pubmedid: 31085176. Pmcid: PMC6945775.
    • Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, Qi J, Sallman DA, Zhang Y, Tu N, Adams WA, Zhang C, Liu J, Cleveland JL, List AF, Wei S. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes. Leukemia. 2019 Aug.33(8):2034-2046. Pubmedid: 30737486. Pmcid: PMC6687540.
    • Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K. African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. J Urol. 2019 Aug.202(2):247-255. Pubmedid: 31107158. Pmcid: PMC7882398.
    • Fernandez MR, Cleveland JL. ATF4-amino acid circuits: a recipe for resistance in melanoma. Embo J. 2018 Oct.37(20). Pubmedid: 30266826. Pmcid: PMC6187218.
    • Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 Nov.27(11):1376-1383. Pubmedid: 30108099. Pmcid: PMC6214732.
    • Hesterberg RS, Cleveland JL, Epling-Burnette PK. Role of Polyamines in Immune Cell Functions. Med Sci (Basel). 2018 Mar.6(1). Pubmedid: 29517999. Pmcid: PMC5872179.
    • Gobert AP, Al-Greene NT, Singh K, Coburn LA, Sierra JC, Verriere TG, Luis PB, Schneider C, Asim M, Allaman MM, Barry DP, Cleveland JL, Destefano Shields CE, Casero RA, Washington MK, Piazuelo MB, Wilson KT. Distinct Immunomodulatory Effects of Spermine Oxidase in Colitis Induced by Epithelial Injury or Infection. Front Immunol. 2018 Jun.9:1242. Pubmedid: 29922289. Pmcid: PMC5996034.
    • Persi E, Duran-Frigola M, Damaghi M, Roush WR, Aloy P, Cleveland JL, Gillies RJ, Ruppin E. Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun. 2018 Jul.9(1):2997. Pubmedid: 30065243. Pmcid: PMC6068141.
    • Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham L, Sudalagunta PR, Wan L, Wang X, Dalton WS, Moscinski LC, Shain KH, Vose J, Cleveland JL, Sotomayor EM, Fu K, Tao J. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018 Dec.128(12):5517-5530. Pubmedid: 30260324. Pmcid: PMC6264635.
    • Singh K, Coburn LA, Asim M, Barry DP, Allaman MM, Shi C, Washington MK, Luis PB, Schneider C, Delgado AG, Piazuelo MB, Cleveland JL, Gobert AP, Wilson KT. Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res. 2018 Aug.78(15):4303-4315. Pubmedid: 29853605. Pmcid: PMC6072585.
    • Kwong T, Ma M, Pan G, Hindra, Yang D, Yang C, Lohman JR, Rudolf JD, Cleveland JL, Shen B. P450-Catalyzed Tailoring Steps in Leinamycin Biosynthesis Featuring Regio- and Stereoselective Hydroxylations and Substrate Promiscuities. Biochemistry-Us. 2018 Aug.57(33):5005-5013. Pubmedid: 30070831. Pmcid: PMC6211295.
    • Huang Q, Chen L, Yang L, Xie X, Gan L, Cleveland JL, Chen J. MDMX acidic domain inhibits p53 DNA binding in vivo and regulates tumorigenesis. Proc Natl Acad Sci U S A. 2018 Apr.115(15):E3368-E3377. Pubmedid: 29581299. Pmcid: PMC5899450.
    • Fernandez MR, Cleveland JL. Metabolic Reprogramming via Targeting CD38 NADase Augments Adoptive T Cell Therapy. Cell Metab. 2018 01.27(1):3-5. Pubmedid: 29320709.
    • Zahedi K, Barone S, Destefano-Shields C, Brooks M, Murray-Stewart T, Dunworth M, Li W, Doherty JR, Hall MA, Smith RD, Cleveland JL, Casero RA, Soleimani M. Activation of endoplasmic reticulum stress response by enhanced polyamine catabolism is important in the mediation of cisplatin-induced acute kidney injury. PLoS One. 2017 Sep.12(9):e0184570. Pubmedid: 28886181. Pmcid: PMC5590979.
    • Hardbower DM, Asim M, Luis PB, Singh K, Barry DP, Yang C, Steeves MA, Cleveland JL, Schneider C, Piazuelo MB, Gobert AP, Wilson KT. Ornithine decarboxylase regulates M1 macrophage activation and mucosal inflammation via histone modifications. Proc Natl Acad Sci U S A. 2017 Jan.114(5):E751-E760. Pubmedid: 28096401. Pmcid: PMC5293075.
    • Getun IV, Wu Z, Fallahi M, Ouizem S, Liu Q, Li W, Costi R, Roush WR, Cleveland JL, Bois PR. Functional Roles of Acetylated Histone Marks at Mouse Meiotic Recombination Hot Spots. Mol Cell Biol. 2017 Feb.37(3). Pubmedid: 27821479. Pmcid: PMC5247613.
    • Cleveland JL, Gray SK, Harte JA, Robison VA, Moorman AC, Gooch BF. Transmission of blood-borne pathogens in US dental health care settings: 2016 update. J Am Dent Assoc. 2016 Sep.147(9):729-738. Pubmedid: 27233680. Pmcid: PMC5084444.
    • Nakanishi S, Cleveland JL. Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer. Amino Acids. 2016 Oct.48(10):2353-2362. Pubmedid: 27357307. Pmcid: PMC5573165.
    • Nair RN, Mishra JK, Li F, Tortosa M, Yang C, Doherty JR, Cameron M, Cleveland JL, Roush WR, Bannister TD. Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors. Medchemcomm. 2016 May.7(5):900-905. Pubmedid: 27347360. Pmcid: PMC4917231.
    • Pan X, Yang C, Cleveland JL, Bannister TD. Synthesis and Cytoxicity of Sempervirine and Analogues. J Org Chem. 2016 Mar.81(5):2194-2200. Pubmedid: 26828413. Pmcid: PMC5573167.
    • Berglund AE, Scott KE, Li W, Yang C, Fernandez MR, Schaub FX, Cleveland JL, Rounbehler RJ. Tristetraprolin disables prostate cancer maintenance by impairing proliferation and metabolic function. Oncotarget. 2016 Dec.7(50):83462-83475. Pubmedid: 27825143. Pmcid: PMC5341258.
    • Rosenberg LH, Cleveland JL, Roush WR, Duckett DR. CK1δ: an exploitable vulnerability in breast cancer. Ann Transl Med. 2016 Dec.4(23):474. Pubmedid: 28090530. Pmcid: PMC5220019.
    • Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Dec.128(25):2960-2975. Pubmedid: 27737891. Pmcid: PMC5179338.
    • Scott KE, Cleveland JL. Lactate Wreaks Havoc on Tumor-Infiltrating T and NK Cells. Cell Metab. 2016 11.24(5):649-650. Pubmedid: 27829133.
    • Liu T, Ma M, Ge HM, Yang C, Cleveland J, Shen B. Synthesis and evaluation of 8,4'-dideshydroxy-leinamycin revealing new insights into the structure-activity relationship of the anticancer natural product leinamycin. Bioorg Med Chem Lett. 2015 Nov.25(21):4899-4902. Pubmedid: 26071634. Pmcid: PMC4607584.
    • Ghalei H, Schaub FX, Doherty JR, Noguchi Y, Roush WR, Cleveland JL, Stroupe ME, Karbstein K. Hrr25/CK1δ-directed release of Ltv1 from pre-40S ribosomes is necessary for ribosome assembly and cell growth. J Cell Biol. 2015 Mar.208(6):745-759. Pubmedid: 25778921. Pmcid: PMC4362465.
    • Schaub FX, Reza MS, Flaveny CA, Li W, Musicant AM, Hoxha S, Guo M, Cleveland JL, Amelio AL. Fluorophore-NanoLuc BRET Reporters Enable Sensitive In Vivo Optical Imaging and Flow Cytometry for Monitoring Tumorigenesis. Cancer Res. 2015 Dec.75(23):5023-5033. Pubmedid: 26424696. Pmcid: PMC4668208.
    • Rosenberg LH, Lafitte M, Quereda V, Grant W, Chen W, Bibian M, Noguchi Y, Fallahi M, Yang C, Chang JC, Roush WR, Cleveland JL, Duckett DR. Therapeutic targeting of casein kinase 1δ in breast cancer. Sci Transl Med. 2015 Dec.7(318):318ra202. Pubmedid: 26676609. Pmcid: PMC4809734.
    • Rosenberg LH, Lafitte M, Grant W, Chen W, Cleveland JL, Duckett DR. Development of an HTS-Compatible Assay for the Discovery of Ulk1 Inhibitors. J Biomol Screen. 2015 Aug.20(7):913-920. Pubmedid: 25851035. Pmcid: PMC4744088.
    • Wang H, Yang C, Doherty JR, Roush WR, Cleveland JL, Bannister TD. Synthesis and structure-activity relationships of pteridine dione and trione monocarboxylate transporter 1 inhibitors. J Med Chem. 2014 Sep.57(17):7317-7324. Pubmedid: 25068893. Pmcid: PMC4161152.
    • Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, Nilsson JA, Cleveland JL, Keller U. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 2014 Sep.124(13):2081-2090. Pubmedid: 25143484. Pmcid: PMC4186537.
    • Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, Hall MA, Amelio AL, Mishra JK, Li F, Tortosa M, Genau HM, Rounbehler RJ, Lu Y, Dang CV, Kumar KG, Butler AA, Bannister TD, Hooper AT, Unsal-Kacmaz K, Roush WR, Cleveland JL. Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res. 2014 Feb.74(3):908-920. Pubmedid: 24285728. Pmcid: PMC3946415.
    • Doherty JR, Nilsson LM, Kuliyev E, Zhu H, Matthew R, Cleveland JL, Mead PE, Roussel MF. Embryonic Expression and Function of the Xenopus Ink4d Cyclin D-Dependent Kinase Inhibitor. Cell Dev Biol. 2014 Feb.3(1). Pubmedid: 25309971. Pmcid: PMC4192657.
    • Seo JW, Ma M, Kwong T, Ju J, Lim SK, Jiang H, Lohman JR, Yang C, Cleveland J, Zazopoulos E, Farnet CM, Shen B. Comparative characterization of the lactimidomycin and iso-migrastatin biosynthetic machineries revealing unusual features for acyltransferase-less type I polyketide synthases and providing an opportunity to engineer new analogues. Biochemistry-Us. 2014 Dec.53(49):7854-7865. Pubmedid: 25405956. Pmcid: PMC4270375.
    • Schaub FX, Cleveland JL. Tipping the MYC-MIZ1 balance: targeting the HUWE1 ubiquitin ligase selectively blocks MYC-activated genes. EMBO Mol Med. 2014 Dec.6(12):1509-1511. Pubmedid: 25368331. Pmcid: PMC4287968.
    • Fallahi M, Amelio AL, Cleveland JL, Rounbehler RJ. CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolin. PLoS One. 2014 Dec.9(12):e115517. Pubmedid: 25541715. Pmcid: PMC4277357.
    • Amelio AL, Fallahi M, Schaub FX, Zhang M, Lawani MB, Alperstein AS, Southern MR, Young BM, Wu L, Zajac-Kaye M, Kaye FJ, Cleveland JL, Conkright MD. CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement. Proc Natl Acad Sci U S A. 2014 Aug.111(32):E3260-E3268. Pubmedid: 25071166. Pmcid: PMC4136562.
    • Jeso V, Yang C, Cameron MD, Cleveland JL, Micalizio GC. Synthesis and SAR of Lehualide B: a marine-derived natural product with potent anti-multiple myeloma activity. Acs Chem Biol. 2014 Aug.8(6):1241-1252. Pubmedid: 23547759. Pmcid: PMC3758376.
    • Lu Y, Wu Y, Feng X, Shen R, Wang JH, Fallahi M, Li W, Yang C, Hankey W, Zhao W, Ganju RK, Li MO, Cleveland JL, Zou X. CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis. J Clin Invest. 2014 Apr.124(4):1672-1684. Pubmedid: 24614102. Pmcid: PMC3973114.
    • Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013 Sep.123(9):3685-3692. Pubmedid: 23999443. Pmcid: PMC3754272.
    • Canterbury DP, Scott KE, Kubo O, Jansen R, Cleveland JL, Micalizio GC. Synthesis of C11-Desmethoxy Soraphen A1α: A natural product analog that inhibits acetyl-CoA carboxylase. ACS Med Chem Lett. 2013 Dec.4(12):1244-1248. Pubmedid: 24639892. Pmcid: PMC3951358.
    • Bibian M, Rahaim RJ, Choi JY, Noguchi Y, Schürer S, Chen W, Nakanishi S, Licht K, Rosenberg LH, Li L, Feng Y, Cameron MD, Duckett DR, Cleveland JL, Roush WR. Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties. Bioorg Med Chem Lett. 2013 Aug.23(15):4374-4380. Pubmedid: 23787102. Pmcid: PMC3783656.
    • Ji H, Wu G, Zhan X, Nolan A, Koh C, De Marzo A, Doan HM, Fan J, Cheadle C, Fallahi M, Cleveland JL, Dang CV, Zeller KI. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS One. 2012 Feb.6(10):e26057. Pubmedid: 22039435. Pmcid: PMC3198433.
    • Valentin-Vega YA, Maclean KH, Tait-Mulder J, Milasta S, Steeves M, Dorsey FC, Cleveland JL, Green DR, Kastan MB. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012 Feb.119(6):1490-1500. Pubmedid: 22144182. Pmcid: PMC3286212.
    • Rounbehler RJ, Fallahi M, Yang C, Steeves MA, Li W, Doherty JR, Schaub FX, Sanduja S, Dixon DA, Blackshear PJ, Cleveland JL. Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Cell. 2012 Aug.150(3):563-574. Pubmedid: 22863009. Pmcid: PMC3422762.
    • Ouellette SP, Dorsey FC, Moshiach S, Cleveland JL, Carabeo RA. Chlamydia species-dependent differences in the growth requirement for lysosomes. PLoS One. 2011 Mar.6(3):e16783. Pubmedid: 21408144. Pmcid: PMC3050816.
    • Joo JH, Dorsey FC, Joshi A, Hennessy-Walters KM, Rose KL, McCastlain K, Zhang J, Iyengar R, Jung CH, Suen DF, Steeves MA, Yang CY, Prater SM, Kim DH, Thompson CB, Youle RJ, Ney PA, Cleveland JL, Kundu M. Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Mol Cell. 2011 Aug.43(4):572-585. Pubmedid: 21855797. Pmcid: PMC3485687.
    • den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010 Sep.116(9):1498-1505. Pubmedid: 20519624. Pmcid: PMC2938839.
    • Old JB, Kratzat S, Hoellein A, Graf S, Nilsson JA, Nilsson L, Nakayama KI, Peschel C, Cleveland JL, Keller UB. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. Mol Cancer Res. 2010 Mar.8(3):353-362. Pubmedid: 20197382. Pmcid: PMC3095030.
    • Keller U, Huber J, Nilsson JA, Fallahi M, Hall MA, Peschel C, Cleveland JL. Myc suppression of Nfkb2 accelerates lymphomagenesis. BMC Cancer. 2010 Jul.10:348. Pubmedid: 20598117. Pmcid: PMC2902445.
    • Steeves MA, Dorsey FC, Cleveland JL. Targeting the autophagy pathway for cancer chemoprevention. Curr Opin Cell Biol. 2010 Apr.22(2):218-225. Pubmedid: 20096553. Pmcid: PMC2854265.
    • Dorsey FC, Rose KL, Coenen S, Prater SM, Cavett V, Cleveland JL, Caldwell-Busby J. Mapping the phosphorylation sites of Ulk1. J Proteome Res. 2009 Nov.8(11):5253-5263. Pubmedid: 19807128.
    • Zhang J, Randall MS, Loyd MR, Dorsey FC, Kundu M, Cleveland JL, Ney PA. Mitochondrial clearance is regulated by Atg7-dependent and -independent mechanisms during reticulocyte maturation. Blood. 2009 Jul.114(1):157-164. Pubmedid: 19417210. Pmcid: PMC2710944.
    • Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M, Cleveland JL. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res. 2009 Jan.69(2):547-553. Pubmedid: 19147568. Pmcid: PMC2749594.
    • Dorsey FC, Steeves MA, Prater SM, Schröter T, Cleveland JL. Monitoring the autophagy pathway in cancer. Methods Enzymol. 2009 Feb.453:251-271. Pubmedid: 19216910.
    • Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE, Yue W, Yu J, Zhang L, Onciu M, Sample JT, Cleveland JL, Zambetti GP. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol. 2008 Sep.28(17):5391-5402. Pubmedid: 18573879. Pmcid: PMC2519737.
    • Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood. 2008 Oct.112(7):2917-2926. Pubmedid: 18641367. Pmcid: PMC2556625.
    • Carew JS, Nawrocki ST, Giles FJ, Cleveland JL. Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. Biologics. 2008 Jun.2(2):201-204. Pubmedid: 19707354. Pmcid: PMC2721364.
    • Carew JS, Nawrocki ST, Reddy VK, Bush D, Rehg JE, Goodwin A, Houghton JA, Casero RA, Marton LJ, Cleveland JL. The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res. 2008 Jun.68(12):4783-4790. Pubmedid: 18559525. Pmcid: PMC2749595.
    • Rodrigues CO, Nerlick ST, White EL, Cleveland JL, King ML. A Myc-Slug (Snail2)/Twist regulatory circuit directs vascular development. Development. 2008 Jun.135(11):1903-1911. Pubmedid: 18469221. Pmcid: PMC2741485.
    • Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest. 2008 Jan.118(1):79-88. Pubmedid: 18097482. Pmcid: PMC2148253.
    • Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, Bursch W, Camougrand N, Cebollero E, Cecconi F, Chen Y, Chin LS, Choi A, Chu CT, Chung J, Clarke PG, Clark RS, Clarke SG, Clavé C, Cleveland JL, Codogno P, Colombo MI, Coto-Montes A, Cregg JM, Cuervo AM, Debnath J, Demarchi F, Dennis PB, Dennis PA, Deretic V, Devenish RJ, Di Sano F, Dice JF, Difiglia M, Dinesh-Kumar S, Distelhorst CW, Djavaheri-Mergny M, Dorsey FC, Dröge W, Dron M, Dunn WA, Duszenko M, Eissa NT, Elazar Z, Esclatine A, Eskelinen EL, Fésüs L, Finley KD, Fuentes JM, Fueyo J, Fujisaki K, Galliot B, Gao FB, Gewirtz DA, Gibson SB, Gohla A, Goldberg AL, Gonzalez R, González-Estévez C, Gorski S, Gottlieb RA, Häussinger D, He YW, Heidenreich K, Hill JA, Høyer-Hansen M, Hu X, Huang WP, Iwasaki A, Jäättelä M, Jackson WT, Jiang X, Jin S, Johansen T, Jung JU, Kadowaki M, Kang C, Kelekar A, Kessel DH, Kiel JA, Kim HP, Kimchi A, Kinsella TJ, Kiselyov K, Kitamoto K, Knecht E, Komatsu M, Kominami E, Kondo S, Kovács AL, Kroemer G, Kuan CY, Kumar R, Kundu M, Landry J, Laporte M, Le W, Lei HY, Lenardo MJ, Levine B, Lieberman A, Lim KL, Lin FC, Liou W, Liu LF, Lopez-Berestein G, López-Otín C, Lu B, Macleod KF, Malorni W, Martinet W, Matsuoka K, Mautner J, Meijer AJ, Meléndez A, Michels P, Miotto G, Mistiaen WP, Mizushima N, Mograbi B, Monastyrska ...
    • Carew JS, Nawrocki ST, Cleveland JL. Modulating autophagy for therapeutic benefit. Autophagy. 2007 Nov.3(5):464-467. Pubmedid: 17495516.
    • Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveldz GC. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol. 2007 May.177(3):563. Pubmedid: 17485494. Pmcid: PMC2064814.
    • Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, MacLean KH, Chung L, Yang C, Spruck C, Boyd K, Reed SI, Cleveland JL. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. Embo J. 2007 May.26(10):2562-2574. Pubmedid: 17464290. Pmcid: PMC1868903.
    • Nilsson LM, Keller UB, Yang C, Nilsson JA, Cleveland JL, Roussel MF. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis. Oncogene. 2007 May.26(20):2833-2839. Pubmedid: 17099725.
    • Maclean KH, Kastan MB, Cleveland JL. Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. Mol Cancer Res. 2007 Jul.5(7):705-711. Pubmedid: 17634425.
    • Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 2007 Jul.110(1):313-322. Pubmedid: 17363733. Pmcid: PMC1896119.
    • Hall MA, Cleveland JL. Clearing the TRAIL for Cancer Therapy. Cancer Cell. 2007 Jul.12(1):4-6. Pubmedid: 17613431.
    • Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res. 2007 Jul.67(14):6987-6994. Pubmedid: 17638911.
    • Schweers RL, Zhang J, Randall MS, Loyd MR, Li W, Dorsey FC, Kundu M, Opferman JT, Cleveland JL, Miller JL, Ney PA. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci U S A. 2007 Dec.104(49):19500-19505. Pubmedid: 18048346. Pmcid: PMC2148318.
    • Sanjuan MA, Dillon CP, Tait SW, Moshiach S, Dorsey F, Connell S, Komatsu M, Tanaka K, Cleveland JL, Withoff S, Green DR. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature. 2007 Dec.450(7173):1253-1257. Pubmedid: 18097414.
    • Wen R, Chen Y, Bai L, Fu G, Schuman J, Dai X, Zeng H, Yang C, Stephan RP, Cleveland JL, Wang D. Essential role of phospholipase C gamma 2 in early B-cell development and Myc-mediated lymphomagenesis. Mol Cell Biol. 2006 Dec.26(24):9364-9376. Pubmedid: 17030619. Pmcid: PMC1698523.
    • Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL. Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene. 2005 Sep.24(41):6231-6240. Pubmedid: 15940251.
    • Bois PR, Brochard VF, Salin-Cantegrel AV, Cleveland JL, Grosveld GC. FoxO1a-cyclic GMP-dependent kinase I interactions orchestrate myoblast fusion. Mol Cell Biol. 2005 Sep.25(17):7645-7656. Pubmedid: 16107711. Pmcid: PMC1190306.
    • Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveld GC. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol. 2005 Sep.170(6):903-912. Pubmedid: 16157701. Pmcid: PMC2171446.
    • Kasper LH, Boussouar F, Boyd K, Xu W, Biesen M, Rehg J, Baudino TA, Cleveland JL, Brindle PK. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. Embo J. 2005 Nov.24(22):3846-3858. Pubmedid: 16237459. Pmcid: PMC1283945.
    • Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, Cleveland JL. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell. 2005 May.7(5):433-444. Pubmedid: 15894264.
    • Cardone M, Kandilci A, Carella C, Nilsson JA, Brennan JA, Sirma S, Ozbek U, Boyd K, Cleveland JL, Grosveld GC. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. Mol Cell Biol. 2005 Mar.25(6):2395-2405. Pubmedid: 15743832. Pmcid: PMC1061619.
    • Guo Y, Cleveland JL, O'Brien TG. Haploinsufficiency for odc modifies mouse skin tumor susceptibility. Cancer Res. 2005 Feb.65(4):1146-1149. Pubmedid: 15734996.
    • Moreno-Miralles I, Pan L, Keates-Baleeiro J, Durst-Goodwin K, Yang C, Kim HG, Thompson MA, Klug CA, Cleveland JL, Hiebert SW. The inv(16) cooperates with ARF haploinsufficiency to induce acute myeloid leukemia. J Biol Chem. 2005 Dec.280(48):40097-40103. Pubmedid: 16199529.
    • Ulett GC, Maclean KH, Nekkalapu S, Cleveland JL, Adderson EE. Mechanisms of group B streptococcal-induced apoptosis of murine macrophages. J Immunol. 2005 Aug.175(4):2555-2562. Pubmedid: 16081829.
    • Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005 Aug.436(7052):807-811. Pubmedid: 16094360. Pmcid: PMC4599579.
    • Cleveland JL, Sherr CJ. Antagonism of Myc functions by Arf. Cancer Cell. 2004 Oct.6(4):309-311. Pubmedid: 15488753.
    • Nilsson JA, Nilsson LM, Keller U, Yokota Y, Boyd K, Cleveland JL. Id2 is dispensable for myc-induced lymphomagenesis. Cancer Res. 2004 Oct.64(20):7296-7301. Pubmedid: 15492249.
    • Nilsson JA, Cleveland JL. Mnt: master regulator of the Max network. Cell Cycle. 2004 May.3(5):588-590. Pubmedid: 15107624.
    • Nilsson JA, Maclean KH, Keller UB, Pendeville H, Baudino TA, Cleveland JL. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol Cell Biol. 2004 Feb.24(4):1560-1569. Pubmedid: 14749372. Pmcid: PMC344188.
    • Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL, Zambetti GP. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003 Oct.4(4):321-328. Pubmedid: 14585359.
    • Maclean KH, Keller UB, Rodriguez-Galindo C, Nilsson JA, Cleveland JL. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol. 2003 Oct.23(20):7256-7270. Pubmedid: 14517295. Pmcid: PMC230315.
    • Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. Embo J. 2003 Mar.22(6):1442-1450. Pubmedid: 12628936. Pmcid: PMC151074.
    • Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003 Dec.22(56):9007-9021. Pubmedid: 14663479.
    • Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A. 2003 Dec.100(26):15930-15935. Pubmedid: 14665695. Pmcid: PMC307670.
    • Cleveland JL. A new piece of the ALS puzzle. Nat Genetics. 2003 Aug.34(4):357-358. Pubmedid: 12923539.
    • Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A, Lees JA, Sherr CJ, Roussel MF, Cleveland JL. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell. 2003 Apr.11(4):905-914. Pubmedid: 12718877.
    • Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN, Cleveland JL. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Gene Dev. 2002 Oct.16(19):2530-2543. Pubmedid: 12368264. Pmcid: PMC187450.
    • Barrett CM, Lewis FL, Roaten JB, Sweatman TW, Israel M, Cleveland JL, Lothstein L. Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther. 2002 May.1(7):469-481. Pubmedid: 12479265.
    • Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med. 2002 Jul.8(7):743-750. Pubmedid: 12091906.
    • Braun JS, Sublett JE, Freyer D, Mitchell TJ, Cleveland JL, Tuomanen EI, Weber JR. Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. J Clin Invest. 2002 Jan.109(1):19-27. Pubmedid: 11781347. Pmcid: PMC150815.
    • Fee BE, Doyle CA, Cleveland JL. A novel Eyes Absent 2 protein is expressed in the human eye. Gene. 2002 Feb.285(1-2):221-228. Pubmedid: 12039049.
    • Clark SW, Fee BE, Cleveland JL. Misexpression of the eyes absent family triggers the apoptotic program. J Biol Chem. 2002 Feb.277(5):3560-3567. Pubmedid: 11700312.
    • Eischen CM, Rehg JE, Korsmeyer SJ, Cleveland JL. Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice. Cancer Res. 2002 Apr.62(7):2184-2191. Pubmedid: 11929842.
    • Magnet KJ, Orr MS, Cleveland JL, Rodriguez-Galindo C, Yang H, Yang C, Di YM, Jain PT, Gewirtz DA. Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells. Biochem Pharmacol. 2001 Sep.62(5):593-602. Pubmedid: 11585056.
    • Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP, Cleveland JL. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene. 2001 Oct.20(48):6983-6993. Pubmedid: 11704823.
    • Pendeville H, Carpino N, Marine JC, Takahashi Y, Muller M, Martial JA, Cleveland JL. The ornithine decarboxylase gene is essential for cell survival during early murine development. Mol Cell Biol. 2001 Oct.21(19):6549-6558. Pubmedid: 11533243. Pmcid: PMC99801.
    • Pestina TI, Cleveland JL, Yang C, Zambetti GP, Jackson CW. Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis. Blood. 2001 Oct.98(7):2084-2090. Pubmedid: 11567994.
    • Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol. 2001 Nov.21(22):7653-7662. Pubmedid: 11604501. Pmcid: PMC99936.
    • Braun JS, Novak R, Murray PJ, Eischen CM, Susin SA, Kroemer G, Halle A, Weber JR, Tuomanen EI, Cleveland JL. Apoptosis-inducing factor mediates microglial and neuronal apoptosis caused by pneumococcus. J Infect Dis. 2001 Nov.184(10):1300-1309. Pubmedid: 11679919.
    • Rodriguez-Galindo C, Poquette CA, Daw NC, Tan M, Meyer WH, Cleveland JL. Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behavior of pediatric osteosarcoma. Med Pediatr Oncol. 2001 Jun.36(6):605-611. Pubmedid: 11344491.
    • Wen R, Wang D, McKay C, Bunting KD, Marine JC, Vanin EF, Zambetti GP, Korsmeyer SJ, Ihle JN, Cleveland JL. Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development. Mol Cell Biol. 2001 Jan.21(2):678-689. Pubmedid: 11134353. Pmcid: PMC86650.
    • Nip J, Strom DK, Eischen CM, Cleveland JL, Zambetti GP, Hiebert SW. E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation. Oncogene. 2001 Feb.20(8):910-920. Pubmedid: 11314026.
    • Baudino TA, Cleveland JL. The Max network gone mad. Mol Cell Biol. 2001 Feb.21(3):691-702. Pubmedid: 11154257. Pmcid: PMC86661.
    • Maclean KH, Cleveland JL, Porter JB. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes. Blood. 2001 Dec.98(13):3831-3839. Pubmedid: 11739193.
    • Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001 Aug.21(15):5063-5070. Pubmedid: 11438662. Pmcid: PMC87232.
    • Drissi R, Zindy F, Roussel MF, Cleveland JL. c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells. J Biol Chem. 2001 Aug.276(32):29994-30001. Pubmedid: 11402027.
    • Maclean K, Yang H, Cleveland JL. Serum suppresses myeloid progenitor apoptosis by regulating iron homeostasis. J Cell Biochem. 2001 Apr.82(1):171-186. Pubmedid: 11400174.
    • Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, Sample JT. EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma. Curr Top Microbiol. 2001.258:153-160. Pubmedid: 11443860.
    • Cleveland JL, Kastan MB. Cancer. A radical approach to treatment. Nature. 2000 Sep.407(6802):309-311. Pubmedid: 11014172.
    • Ruf IK, Rhyne PW, Yang C, Cleveland JL, Sample JT. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol. 2000 Nov.74(21):10223-10228. Pubmedid: 11024153. Pmcid: PMC102063.
    • Inoue K, Wen R, Rehg JE, Adachi M, Cleveland JL, Roussel MF, Sherr CJ. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Gene Dev. 2000 Jul.14(14):1797-1809. Pubmedid: 10898794. Pmcid: PMC316790.
    • Wang D, Feng J, Wen R, Marine JC, Sangster MY, Parganas E, Hoffmeyer A, Jackson CW, Cleveland JL, Murray PJ, Ihle JN. Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity. 2000 Jul.13(1):25-35. Pubmedid: 10933392.
    • Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Gene Dev. 2000 Dec.14(24):3102-3114. Pubmedid: 11124803. Pmcid: PMC317128.
    • Braun JS, Tuomanen EI, Cleveland JL. Neuroprotection by caspase inhibitors. Expert Opin Inv Drug. 1999 Oct.8(10):1599-1610. Pubmedid: 11139813.
    • Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Gene Dev. 1999 Oct.13(20):2658-2669. Pubmedid: 10541552. Pmcid: PMC317106.
    • Dai H, Kramer DL, Yang C, Murti KG, Porter CW, Cleveland JL. The polyamine oxidase inhibitor MDL-72,527 selectively induces apoptosis of transformed hematopoietic cells through lysosomotropic effects. Cancer Res. 1999 Oct.59(19):4944-4954. Pubmedid: 10519408.
    • Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, Sample JT. Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol. 1999 Mar.19(3):1651-1660. Pubmedid: 10022853. Pmcid: PMC83959.
    • Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, Tuomanen EI. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med. 1999 Mar.5(3):298-302. Pubmedid: 10086385.
    • Florio M, Hernandez MC, Yang H, Shu HK, Cleveland JL, Israel MA. Id2 promotes apoptosis by a novel mechanism independent of dimerization to basic helix-loop-helix factors. Mol Cell Biol. 1998 Sep.18(9):5435-5444. Pubmedid: 9710627. Pmcid: PMC109128.
    • Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol. 1998 Jul.18(7):3735-3743. Pubmedid: 9632756. Pmcid: PMC108956.
    • Strom DK, Cleveland JL, Chellappan S, Nip J, Hiebert SW. E2F-1 and E2F-3 are functionally distinct in their ability to promote myeloid cell cycle progression and block granulocyte differentiation. Cell Growth Differ. 1998 Jan.9(1):59-69. Pubmedid: 9438389.
    • Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Gene Dev. 1998 Aug.12(15):2424-2433. Pubmedid: 9694806. Pmcid: PMC317045.
    • Packham G, White EL, Eischen CM, Yang H, Parganas E, Ihle JN, Grillot DA, Zambetti GP, Nuñez G, Cleveland JL. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Gene Dev. 1998 Aug.12(16):2475-2487. Pubmedid: 9716401. Pmcid: PMC317092.
    • Quelle FW, Wang J, Feng J, Wang D, Cleveland JL, Ihle JN, Zambetti GP. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Gene Dev. 1998 Apr.12(8):1099-1107. Pubmedid: 9553040. Pmcid: PMC316716.
    • Packham G, Cleveland JL. Induction of ornithine decarboxylase by IL-3 is mediated by sequential c-Myc-independent and c-Myc-dependent pathways. Oncogene. 1997 Sep.15(10):1219-1232. Pubmedid: 9294616.
    • Zhan Y, Cleveland JL, Stevens JL. A role for c-myc in chemically induced renal-cell death. Mol Cell Biol. 1997 Nov.17(11):6755-6764. Pubmedid: 9343440. Pmcid: PMC232530.
    • Ikushima S, Inukai T, Inaba T, Nimer SD, Cleveland JL, Look AT. Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. Proc Natl Acad Sci U S A. 1997 Mar.94(6):2609-2614. Pubmedid: 9122243. Pmcid: PMC20136.
    • Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol. 1997 Mar.17(3):1049-1056. Pubmedid: 9032231. Pmcid: PMC231829.
    • Packham G, Lahti JM, Fee BE, Gawn JM, Coustan-Smith E, Campana D, Douglas I, Kidd VJ, Ghosh S, Cleveland JL. Fas activates NF-kappaB and induces apoptosis in T-cell lines by signaling pathways distinct from those induced by TNF-alpha. Cell Death Differ. 1997 Feb.4(2):130-139. Pubmedid: 16465219.
    • Packham G, Brimmell M, Cleveland JL. Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation. Biochem J. 1997 Dec.328 ( Pt 3):807-813. Pubmedid: 9396724. Pmcid: PMC1218990.
    • Brewer JW, Cleveland JL, Hendershot LM. A pathway distinct from the mammalian unfolded protein response regulates expression of endoplasmic reticulum chaperones in non-stressed cells. Embo J. 1997 Dec.16(23):7207-7216. Pubmedid: 9384597. Pmcid: PMC1170321.
    • Packham G, Porter CW, Cleveland JL. c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene. 1996 Aug.13(3):461-469. Pubmedid: 8760287.
    • Packham G, Ashmun RA, Cleveland JL. Cytokines suppress apoptosis independent of increases in reactive oxygen levels. J Immunol. 1996 Apr.156(8):2792-2800. Pubmedid: 8609398.
    • Katzav S, Packham G, Sutherland M, Aroca P, Santos E, Cleveland JL. Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function. Oncogene. 1995 Sep.11(6):1079-1088. Pubmedid: 7566967.
    • Ofir R, Novick I, Krup M, Cleveland JL, Ihle JN, Weinstein Y. Structural and functional analysis of the promoter of the murine V gamma 1.1 T cell receptor gene. Eur J Immunol. 1995 Nov.25(11):3070-3078. Pubmedid: 7489745.
    • Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell. 1995 May.81(4):479-482. Pubmedid: 7758103.
    • Weinstein Y, Askew DS, Miura O, Cleveland JL, Ihle JN. Regulation of T cell receptor gamma gene expression by cytokines in murine hematopoietic cells. Eur Cytokine Netw. 1995 Mar.6(2):97-102. Pubmedid: 7578993.
    • Quelle FW, Shimoda K, Thierfelder W, Fischer C, Kim A, Ruben SM, Cleveland JL, Pierce JH, Keegan AD, Nelms K. Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol Cell Biol. 1995 Jun.15(6):3336-3343. Pubmedid: 7760829. Pmcid: PMC230567.
    • Matsugi T, Kreider BL, Delwel R, Cleveland JL, Askew DS, Ihle JN. The Evi-1 zinc finger myeloid transforming protein binds to genomic fragments containing (GATA)n sequences. Oncogene. 1995 Jul.11(1):191-198. Pubmedid: 7624127.
    • Packham G, Cleveland JL. c-Myc and apoptosis. Biochim Biophys Acta. 1995 Jul.1242(1):11-28. Pubmedid: 7626652.
    • Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, Cleveland JL. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol. 1995 Dec.15(12):6864-6874. Pubmedid: 8524253. Pmcid: PMC230941.
    • Packham G, Cleveland JL. The role of ornithine decarboxylase in c-Myc-induced apoptosis. Curr Top Microbiol. 1995.194:283-290. Pubmedid: 7895500.
    • Packham G, Cleveland JL. Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol Cell Biol. 1994 Sep.14(9):5741-5747. Pubmedid: 8065308. Pmcid: PMC359099.
    • Conley ME, Fitch-Hilgenberg ME, Cleveland JL, Parolini O, Rohrer J. Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase. Hum Mol Genet. 1994 Oct.3(10):1751-1756. Pubmedid: 7849697.
    • Roussel MF, Davis JN, Cleveland JL, Ghysdael J, Hiebert SW. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene. 1994 Feb.9(2):405-415. Pubmedid: 8290253.
    • Cleveland JL, Troppmair J, Packham G, Askew DS, Lloyd P, González-Garcia M, Nuñez G, Ihle JN, Rapp UR. v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene. 1994 Aug.9(8):2217-2226. Pubmedid: 8036007.
    • Packham G, Bello-Fernandez C, Cleveland JL. Position and orientation independent transactivation by c-Myc. Cell Mol Biol Res. 1994.40(7-8):699-706. Pubmedid: 7787888.
    • Silvennoinen O, Witthuhn BA, Quelle FW, Cleveland JL, Yi T, Ihle JN. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci U S A. 1993 Sep.90(18):8429-8433. Pubmedid: 8378315. Pmcid: PMC47370.
    • Armstrong E, Korhonen J, Silvennoinen O, Cleveland JL, Lieberman MA, Alitalo R. Expression of tie receptor tyrosine kinase in leukemia cell lines. Leukemia. 1993 Oct.7(10):1585-1591. Pubmedid: 8412320.
    • Askew DS, Ihle JN, Cleveland JL. Activation of apoptosis associated with enforced myc expression in myeloid progenitor cells is dominant to the suppression of apoptosis by interleukin-3 or erythropoietin. Blood. 1993 Oct.82(7):2079-2087. Pubmedid: 8400257.
    • Miura O, Cleveland JL, Ihle JN. Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors. Mol Cell Biol. 1993 Mar.13(3):1788-1795. Pubmedid: 8382775. Pmcid: PMC359491.
    • Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A. 1993 Aug.90(16):7804-7808. Pubmedid: 8356088. Pmcid: PMC47231.
    • Okuda T, Cleveland JL, Downing JR. PCTAIRE-1 and PCTAIRE-3, two members of a novel cdc2/CDC28-related protein kinase gene family. Oncogene. 1992 Nov.7(11):2249-2258. Pubmedid: 1437147.
    • Rock CO, Cleveland JL, Jackowski S. Macrophage growth arrest by cyclic AMP defines a distinct checkpoint in the mid-G1 stage of the cell cycle and overrides constitutive c-myc expression. Mol Cell Biol. 1992 May.12(5):2351-2358. Pubmedid: 1373814. Pmcid: PMC364407.
    • Yi TL, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol. 1992 Feb.12(2):836-846. Pubmedid: 1732748. Pmcid: PMC364317.
    • Reynolds AB, Herbert L, Cleveland JL, Berg ST, Gaut JR. p120, a novel substrate of protein tyrosine kinase receptors and of p60v-src, is related to cadherin-binding factors beta-catenin, plakoglobin and armadillo. Oncogene. 1992 Dec.7(12):2439-2445. Pubmedid: 1334250.
    • Duyao MP, Kessler DJ, Spicer DB, Bartholomew C, Cleveland JL, Siekevitz M, Sonenshein GE. Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B. J Biol Chem. 1992 Aug.267(23):16288-16291. Pubmedid: 1644814.
    • Troppmair J, Cleveland JL, Askew DS, Rapp UR. v-Raf/v-Myc synergism in abrogation of IL-3 dependence: v-Raf suppresses apoptosis. Curr Top Microbiol. 1992.182:453-460. Pubmedid: 1490385.
    • Bello-Fernandez C, Cleveland JL. c-myc transactivates the ornithine decarboxylase gene. Curr Top Microbiol. 1992.182:445-452. Pubmedid: 1490383.
    • Roussel MF, Cleveland JL, Shurtleff SA, Sherr CJ. Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. Nature. 1991 Sep.353(6342):361-363. Pubmedid: 1833648.
    • Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 1991 Oct.6(10):1915-1922. Pubmedid: 1923514.
    • Yi T, Cleveland JL, Ihle JN. Identification of novel protein tyrosine phosphatases of hematopoietic cells by polymerase chain reaction amplification. Blood. 1991 Nov.78(9):2222-2228. Pubmedid: 1932742.
    • Katzav S, Cleveland JL, Heslop HE, Pulido D. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol. 1991 Apr.11(4):1912-1920. Pubmedid: 2005887. Pmcid: PMC359873.
    • Storm SM, Cleveland JL, Rapp UR. Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene. 1990 Mar.5(3):345-351. Pubmedid: 1690378.
    • Heidecker G, Huleihel M, Cleveland JL, Kolch W, Beck TW, Lloyd P, Pawson T, Rapp UR. Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol. 1990 Jun.10(6):2503-2512. Pubmedid: 2188091. Pmcid: PMC360607.
    • Beck TW, Brennscheidt U, Sithanandam G, Cleveland J, Rapp UR. Molecular organization of the human Raf-1 promoter region. Mol Cell Biol. 1990 Jul.10(7):3325-3333. Pubmedid: 1694010. Pmcid: PMC360752.
    • Principato M, Cleveland JL, Rapp UR, Holmes KL, Pierce JH, Morse HC, Klinken SP. Transformation of murine bone marrow cells with combined v-raf-v-myc oncogenes yields clonally related mature B cells and macrophages. Mol Cell Biol. 1990 Jul.10(7):3562-3568. Pubmedid: 2162474. Pmcid: PMC360791.
    • Weinstein Y, Morishita K, Cleveland JL, Ihle JN. Interleukin 3 (IL-3) induces transcription from nonrearranged T cell receptor gamma loci in IL-3-dependent cell lines. J Exp Med. 1989 Jun.169(6):2059-2071. Pubmedid: 2543731. Pmcid: PMC2189342.
    • Cleveland JL, Dean M, Rosenberg N, Wang JY, Rapp UR. Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving c-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl. Mol Cell Biol. 1989 Dec.9(12):5685-5695. Pubmedid: 2555703. Pmcid: PMC363740.
    • Horton WE, Cleveland J, Rapp U, Nemuth G, Bolander M, Doege K, Yamada Y, Hassell JR. An established rat cell line expressing chondrocyte properties. Exp Cell Res. 1988 Oct.178(2):457-468. Pubmedid: 3049123.
    • Greil K, Gattringer C, Fasching B, Cleveland J, Thaler J, Radaskiewicz T, Gastl G, Huber C, Rapp U, Huber H. abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status. Int J Cancer. 1988 Oct.42(4):529-538. Pubmedid: 3049401.
    • Farrar WL, Vinocour M, Cleveland JL, Harel-Bellan A. Regulation of ornithine decarboxylase activity by IL-2 and cyclic AMP. J Immunol. 1988 Aug.141(3):967-971. Pubmedid: 2840461.
    • Dean M, Cleveland J, Kim HY, Campisi J, Levine RA, Ihle JN, Rapp U. Deregulation of the c-myc and N-myc genes in transformed cells. Curr Top Microbiol. 1988.141:216-222. Pubmedid: 3215051.
    • Troppmair J, Huleihel M, Cleveland J, Mushinski JF, Kurie J, Morse HC, Wax JS, Potter M, Rapp UR. Plasmacytoma induction by J series of v-myc recombinant retroviruses: evidence for the requirement of two (raf and myc) oncogenes for transformation. Curr Top Microbiol. 1988.141:110-114. Pubmedid: 3215044.
    • Rapp UR, Heidecker G, Huleihel M, Cleveland JL, Choi WC, Pawson T, Ihle JN, Anderson WB. raf family serine/threonine protein kinases in mitogen signal transduction. Cold Spring Harb Symp Quant Biol. 1988.53 Pt 1:173-184. Pubmedid: 2978288.
    • Cleveland JL, Dean M, Wang JY, Hedge AM, Ihle JN, Rapp UR. Abrogation of IL-3 dependence of myeloid FDC-P1 cells by tyrosine kinase oncogenes is associated with induction of c-myc. Curr Top Microbiol. 1988.141:300-309. Pubmedid: 3265092.
    • Principato M, Klinken SP, Cleveland JL, Rapp UR, Holmes KL, Pierce JH, Morse HC. In vitro transformation of murine bone marrow cells with a v-raf/v-myc retrovirus yields clonally related mature B cells and macrophages. Curr Top Microbiol. 1988.141:31-41. Pubmedid: 3265093.
    • Cleveland JL, Huleihel M, Bressler P, Siebenlist U, Akiyama L, Eisenman RN, Rapp UR. Negative regulation of c-myc transcription involves myc family proteins. Oncogene Res. 1988.3(4):357-375. Pubmedid: 2976141.
    • Farrar WL, Evans SW, Rapp UR, Cleveland JL. Effects of anti-proliferative cyclic AMP on interleukin 2-stimulated gene expression. J Immunol. 1987 Sep.139(6):2075-2080. Pubmedid: 3040863.
    • Cleveland JL, Rapp UR, Farrar WL. Role of c-myc and other genes in interleukin 2 regulated CT6 T lymphocytes and their malignant variants. J Immunol. 1987 May.138(10):3495-3504. Pubmedid: 3106484.
    • Weinstein Y, Cleveland JL, Askew DS, Rapp UR, Ihle JN. Insertion and truncation of c-myb by murine leukemia virus in a myeloid cell line derived from cultures of normal hematopoietic cells. J Virol. 1987 Jul.61(7):2339-2343. Pubmedid: 2884332. Pmcid: PMC283705.
    • Dean M, Cleveland JL, Rapp UR, Ihle JN. Role of myc in the abrogation of IL3 dependence of myeloid FDC-P1 cells. Oncogene Res. 1987 Aug.1(3):279-296. Pubmedid: 2453016.
    • Rapp UR, Storm SM, Cleveland JL. Oncogenes: clinical relevance. Haematol Blood Transfus. 1987.31:450-459. Pubmedid: 3327780.
    • Ihle JN, Weinstein Y, Rapp UR, Cleveland JL, Reddy EP. Mechanisms in interleukin 3 regulated growth and differentiation. Adv Exp Med Biol. 1987.213:149-162. Pubmedid: 3498294.
    • Morse HC, Hartley JW, Fredrickson TN, Yetter RA, Majumdar C, Cleveland JL, Rapp UR. Recombinant murine retroviruses containing avian v-myc induce a wide spectrum of neoplasms in newborn mice. Proc Natl Acad Sci U S A. 1986 Sep.83(18):6868-6872. Pubmedid: 3018749. Pmcid: PMC386611.
    • Huebner K, ar-Rushdi A, Griffin CA, Isobe M, Kozak C, Emanuel BS, Nagarajan L, Cleveland JL, Bonner TI, Goldsborough MD. Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human. Proc Natl Acad Sci U S A. 1986 Jun.83(11):3934-3938. Pubmedid: 3520560. Pmcid: PMC323639.
    • Huleihel M, Goldsborough M, Cleveland J, Gunnell M, Bonner T, Rapp UR. Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol Cell Biol. 1986 Jul.6(7):2655-2662. Pubmedid: 3491291. Pmcid: PMC367822.
    • Farrar WL, Cleveland JL, Beckner SK, Bonvini E, Evans SW. Biochemical and molecular events associated with interleukin 2 regulation of lymphocyte proliferation. Immunol Rev. 1986 Aug.92:49-65. Pubmedid: 3091482.
    • Cleveland JL, Jansen HW, Bister K, Fredrickson TN, Morse HC, Ihle JN, Rapp UR. Interaction between Raf and Myc oncogenes in transformation in vivo and in vitro. J Cell Biochem. 1986.30(3):195-218. Pubmedid: 3084503.
    • Rapp UR, Cleveland JL, Storm SM, Beck TW, Huleihel M. Transformation by raf and myc oncogenes. Princess Takamatsu Symp. 1986.17:55-74. Pubmedid: 3332021.
    • Morse HC, Hartley JW, Fredrickson TN, Yetter RA, Cleveland JL, Majumdar C, Rapp UR. Tumors of newborn NFS/N mice infected with murine retroviruses containing avian v-myc. Curr Top Microbiol. 1986.132:17-22. Pubmedid: 3024912.
    • Cleveland JL, Weinstein Y, Ihle JN, Askew DS, Rapp UR. Transformation and insertional mutagenesis in vitro of primary hematopoietic stem cell cultures. Curr Top Microbiol. 1986.132:44-54. Pubmedid: 3024923.
    • Rapp UR, Cleveland JL, Brightman K, Scott A, Ihle JN. Abrogation of IL-3 and IL-2 dependence by recombinant murine retroviruses expressing v-myc oncogenes. Nature. 1985 Oct.317(6036):434-438. Pubmedid: 3930972.
    • Rapp UR, Cleveland JL, Fredrickson TN, Holmes KL, Morse HC, Jansen HW, Patschinsky T, Bister K. Rapid induction of hemopoietic neoplasms in newborn mice by a raf(mil)/myc recombinant murine retrovirus. J Virol. 1985 Jul.55(1):23-33. Pubmedid: 4009794. Pmcid: PMC254893.
    • Blasi E, Mathieson BJ, Varesio L, Cleveland JL, Borchert PA, Rapp UR. Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus. Nature. 1985 Dec.318(6047):667-670. Pubmedid: 4079980.
  • Grants

    • Title: State of Florida Appropriation
      Sponsor: State of Florida
      PI: Cleveland, J.
    • Title: SOW for project management, alliance management, and Executive Sponsors in Major Alliance with Turnstone
      Sponsor: Turnstone Biologics
      PI: Cleveland, J.
    • Title: CCSG Developmental Project: Pilot Project for Tobacco Cessation and Machine Learning
      Sponsor: Nat Institutes of Health
      PI: Cleveland, J., PI: Vidrine, J.
    • Title: Moffitt Cancer Center Support Grant Years 24-27
      Sponsor: Nat Institutes of Health
      PI: Cleveland, J., Project PI: Kanetsky, P., Project PI: Kissil, J., Project PI: Brandon, T., Project PI: Conejo-Garcia, J., Project PI: Duckett, D., Project PI: Gray, J., Project PI: Jim, H., Project PI: Locke, F., Core PI/Director: Springer, B., Core PI/Director: Vadaparampil, S., Core PI/Director: Wright, K., Core PI/Director: Rodriguez, P.
    • Title: Determinants of Cancer Survivorship Among People Living with HIV (HIV/AIDS/Aging Cancer)
      Sponsor: Nat Institutes of Health
      PI: Cleveland, J., Project PI: Islam, J.
    • Title: The role of Accelerated Biological Aging in HIV control and Non-AIDS-defining Cancer Risk (Biospecimens/Biocohort)
      Sponsor: Nat Institutes of Health
      PI: Cleveland, J., Project PI: Coghill, A.
    • Title: St of FL Appropriation-CMRC Developmental Funds-10
      Sponsor: State of Florida
      PI (Contact): Cleveland, J., PI: Smalley, K.
    • Title: Identifying Metabolic Vulnerabilities in Lung Cancer
      Sponsor: Nat Institutes of Health
      PI (Contact): Flores, E., PI (MPI): Haura, E., Project PI: DeNicola, G., Project PI: Rodriguez, P., Project PI: Cleveland, J., Core PI/Director: Fridley, B., Core PI/Director: Cress, D., Core PI/Director: Koomen, J.
    • Title: St of FL Appropriation-CET Developmental Funds-12
      Sponsor: State of Florida
      PI (Contact): Cleveland, J., PI: Anderson, A.
    • Title: St of FL Appropriation-CIRC Developmental Funds- 09
      Sponsor: State of Florida
      PI (Contact): Cleveland, J., PI: Giuliano, A.
    • Title: St of FL Appropriation-Lung CoE Developmental Funds-11
      Sponsor: State of Florida
      PI (Contact): Haura, E., PI: Cleveland, J.
    • Title: Targeted degradation of RNAs by using small molecules
      Sponsor: Nat Institutes of Health
      PI: Cleveland, J.
    • Title: New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
      Sponsor: Nat Institutes of Health
      PI: Cleveland, J.
    • Title: State of FL-License Plate Funds
      Sponsor: State of Florida
      PI: Cleveland, J.

Find a Researcher Search